-
2022-502122-41-00
5
2021-05-11
Clear cell renal cancer
-
2023-507970-42-00
5
2021-03-31
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-504805-35-00
9
2020-10-22
Lymphoma of B-cell origin
-
2022-502084-38-00
5
2020-10-16
Cancer
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2022-502887-19-00
5
2020-08-18
Diffuse Large B-Cell Lymphoma
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2023-503831-17-00
4
2019-12-23
The treatment of participants with HRRm and/or HRD-positive cancer
-
2022-502604-67-00
10
2019-12-20
Malignant pleural mesothelioma (MPM)
-
2023-507732-20-00
5
2019-11-29
Advanced epithelial ovarian cancer stage III-IV
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer
-
2023-506832-33-00
5
2019-11-06
haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
-
2023-509276-42-00
6
2019-10-30
Children and Adolescents with Cancers Harboring V600 mutation.
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2023-504624-25-00
4
2019-09-26
Advanced Non-Small Cell Lung Cancer
-
2023-504593-38-00
9
2019-08-12
Osteogenesis Imperfecta (OI) type III and severe type IV.
Severe type
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer